AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01200524
Drug: AZD2423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tablet
Trial: NCT01200524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01978418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given once as a dose of four puffs at 30-60 minutes of age
Trial: NCT00997880
Drug: Rosuvastatin calcium 40mg
RxNorm normalized name: Rosuvastatin Calcium 40mg Oral tablet
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin calcium 40mg
Trial: NCT01214603
Drug: LY2090314
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT04115449
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline as a placebo will be infused over a period of ten minutes
Trial: NCT00997880
Drug: Rosuvastatin calcium10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10mg
Trial: NCT01359007
Drug: Irinotecan, Oxaliplatin, Leucovorin, 5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU 2400 mg/m2 IV continuous infusion for 46-48 hours Days 1-3 for 2 weeks 5-FU 400 mg/m2 IV Bolus Day 1 Oxaliplatin 85 mg/m2 IV over 120min +/-30 min. Day 1 Irinotecan 180 mg/m2 IV to run over 90 min +/- 30 min Day 1 Leucovorin (Before bolus 5-FU) 400 mg/m2 IV over 120 min. +/- 30 Day 1 May give oxaliplatin and leucovorin concurrently
Trial: NCT00384033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets and capsules, once daily dosing for 8 weeks
Trial: NCT01134731
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-5 placebo capsules
Trial: NCT01298310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for injection
Trial: NCT00689078
Drug: Prednisolone Acetate 1%
RxNorm normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
Trial: NCT00689078
Drug: Prednisolone Acetate 0.12%
RxNorm normalized name: PREDNISOLONE ACETATE 0.12% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
Trial: NCT02010723
Drug: sclerotherapy with aethoxysclerol foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: foam sclerotherapy with aethoxysclerol foam
Trial: NCT00689078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
Trial: NCT01856907
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will evaluate effect of lifestyle and diet only
Trial: NCT00260325
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03292575
Drug: Anticoagulants
RxNorm normalized name: ANTICOAGULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00735683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: includes diet, physical activity, and lifestyle modification
Trial: NCT02033525
Drug: XCEL-M-ALPHA and standard rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)
Trial: NCT02595138
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01944033
Drug: Bricanyl/Iprovent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Terbutaline sulfate (2ml) + 0,5 mg Ipratropium bromide (2ml) + 1ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
Trial: NCT00735241
Drug: FOLFOX6 cycles 1-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 60 mg/m2, IV infusion, q 2 weeks Leucovorin 200 mg/m2, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
Trial: NCT00735241
Drug: FOLFOX6 cycles 4 onwards
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m2 given, IV infusion, q 2 weeks Leucovorin 200 mg/m2 given, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
Trial: NCT01561378
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microliters of normal saline will be administered per nostril using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
Trial: NCT01460368
Drug: LY2409021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01460368
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00973674
Drug: Premarin IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time dose of Premarin IV
Trial: NCT00973674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time dose of Placebo
Trial: NCT00071396
Drug: Campath-1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day Continuous infusion by vein (IV) for 6 days then given twice a week for remaining three weeks as 30 mg injection under skin to complete one treatment course of 4 weeks.
Trial: NCT01212107
Drug: FGF Receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2874455 administered orally.
Trial: NCT01212107
Drug: Phosphate Binders
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03503136
Drug: docetaxel, nedaplatin, and capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive docetaxel(60 mg/m2 on day 1), nedaplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
Trial: NCT03503136
Drug: docetaxel, cisplatin, and fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
Trial: NCT03503136
Drug: docetaxel, cisplatin, and capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive docetaxel(60 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
Trial: NCT03503136
Drug: docetaxel, nedaplatin, and fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive docetaxel (60mg/m2 on day 1), nedaplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
Trial: NCT04148391
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules.
Trial: NCT00005878
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00810693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo tid orally for 12 weeks
Trial: NCT00891293
Drug: Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)
RxNorm normalized name: omega-3 acid ethyl esters (USP) 1000 MG [Lovaza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label Antara (fenofibrate) + open-label Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
Trial: NCT01768767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00769522
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cycle 1-6: 250 mg/m² i.v., days 1-3, q28d
Trial: NCT04162665
Drug: Standard of care chemotherapy regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The recommendations are CAPOX, FOLFOX, or FLT.
Trial: NCT02572609
Drug: Mucosolvan ® adult syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01783054
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive gemcitabine at 1000 mg/m2 and abraxane at 125 mg/m2 intravenously on days 1, 8 and 15 of a 28 day cycle for 2 cycles
Trial: NCT00295893
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02127710
Drug: AZD6094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor.
Trial: NCT00295893
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02990533
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02979197
Drug: OE 200 mg celecoxib capsule
RxNorm normalized name: celecoxib 200 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02979197
Drug: Matched placebo for OE celecoxib capsule
RxNorm normalized name: celecoxib Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03661645
Drug: 10 mg IV dexamethasone & 6 day oral methylprednisolone taper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: 6-day oral methylprednisolone (glucocorticoid) taper course The oral methylprednisolone taper course will begin on the day of surgery and will include 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day.~Drug:10 mg intravenous (IV) dexamethasone
Trial: NCT02081183
Drug: Cyclophosphamide, Maintenance Phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-1 g/m\^2 IV pulse once every 3 months
Trial: NCT02081183
Drug: Cyclophosphamide, Induction Phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 - 1 g/m\^2 IV pulse once per month
Trial: NCT00003927
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003927
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02631109
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg/m2 day1
Trial: NCT05576675
Drug: sufentanil + nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sufentanil 100 μ g + nalbuphine 40 mg
Trial: NCT05576675
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sufentanil 200 μ g
Trial: NCT00795847
Drug: Preminent (losartan/hydrochlorothiazide combination drug)
RxNorm normalized name: hydrochlorothiazide / losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.
Trial: NCT00202059
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03867383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 milliliters normal saline
Trial: NCT00036413
Drug: TCH346
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01174121
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X2 days over 1 hr.
Trial: NCT01626378
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be administered twice daily. The placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
Trial: NCT03610360
Drug: MesoPher
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Masophen PM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in Arm A will undergo leukapheresis to obtain monocytes from which dendritic cells will be generated. These dendritic cells will be loaded in vitro with an allogeneic tumor cell lysate (PheraLys). Treatment with autologous dendritic cells loaded with PheraLys is called MesoPher
Trial: NCT02213354
Drug: MF59
RxNorm normalized name: vaccine adjuvant emulsion MF59C.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
Trial: NCT00561769
Drug: Norditropin pen
RxNorm normalized name: somatropin Pen Injector [Norditropin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 IU per day
Trial: NCT01821027
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 40 mg tablet taken orally (by mouth) on Day 1 and Day 7.
Trial: NCT03415828
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradiscal infiltration of steroids
Trial: NCT01861327
Drug: CO2
RxNorm normalized name: CO2 (ISBT symbol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carbon dioxide (CO2) as arterial contrast media
Trial: NCT02592694
Drug: cocktail
RxNorm normalized name: Cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocktail (tirofiban, bivalirudin, tenecteplase) will be given in addition to thrombus aspiration
Trial: NCT04143893
Drug: Optimal medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with cardiogenic shock who received optimal medical treatment including vasopressor
Trial: NCT01879514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo includes placebo of ZiBuGanShen Granule and placebo of BuShenTongLuo Granule
Trial: NCT01203631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose administered subcutaneously (s.c., under the skin)
Trial: NCT01470937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acarbose placebo
Trial: NCT03227328
Drug: concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6 inhibitor:~* palbociclib~* ribociclib~* abemaciclib~Endocrine therapy:~* non-steroidal or steroidal AI~* fulvestrant
Trial: NCT03227328
Drug: chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Chemotherapy regimens will be classified as:~* anthracycline + taxane,~* taxane,~* anthracycline,~* capecitabine / fluoropyrimidines,~* others.~Endocrine therapy:~* non-steroidal or steroidal AI~* fulvestrant
Trial: NCT04638400
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin administered daily for 6 weeks
Trial: NCT01805440
Drug: Uridine
RxNorm normalized name: Uridine
DrugBank: Uridine (DB02745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uridine is the active treatment in this clinical trial.
Trial: NCT01805440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill placebo is the inactive treatment comparator in this clinical trial.
Trial: NCT00261183
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03804008
Drug: Ultrasound-guided corticosteroid injection
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid 20mg/ml + 1 ml Lidocain 10 mg7ml. The skin is cleansed with Chlorhexidine alcohol 0.5 %. The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness. Participants are asked to start performing the exercise as soon as they feel ready but not before 24 hours after the injection. Furthermore, they are asked not to progress the method used to achieve 8RM when they start to do the exercise after the injection until Week 3 of the exercise programme. If standing on both feet was sufficient to achieve 8RM at baseline, the participant must not perform the exercise single-legged or to wear a backpack with weights after the injection regardless of any pain reduction afforded by the injection.
Trial: NCT02493725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03911713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to IVA.
Trial: NCT03911713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos matched to VX-561.
Trial: NCT01173939
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg/day or 10 mg/day of pravastatin will be administered orally for 36 months, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<120 mg/dL (JASGL 2007 target level) as quickly as possible. (Maximum dose increase of pravastatin: 20 mg/day)
Trial: NCT01173939
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/day or 10 mg/day of rosuvastatin will be administered orally for 36 months based on the LDL-C level of the subject, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<70 mg/dL as quickly as possible. (Maximum dose increase to rosuvastatin: 20 mg/day)
Trial: NCT02219438
Drug: Basal
RxNorm normalized name: Basaljel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An adductor canal catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for a total of 8 hours.
Trial: NCT01931592
Drug: ESBL eradication regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
Trial: NCT01931592
Drug: Placebo ESBL eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
Trial: NCT04644003
Drug: STP1
RxNorm normalized name: TRACHEAL SUCTION SET 14FR M#DYNCSTP14TH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STP1 is a combination of two drugs, a phosphodiesterase (PDE) inhibitor and an NKCC1 inhibitor
Trial: NCT04644003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication (capsule and tablet) identical in appearance to active medication
Trial: NCT00482313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill
Trial: NCT01745328
Drug: LVX-AMX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.
Trial: NCT01745328
Drug: TCM
RxNorm normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL GEL [TCM Brand Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject is treated with TCM for 4 weeks.
Trial: NCT01745328
Drug: LVX-AMX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment with placebo from 2 to 4 weeks.
Trial: NCT02398656
Drug: Antiplatelet treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin (single agent) will be the choice of most physicians, some Investigators will chose to use the combination of aspirin and clopidogrel.
Trial: NCT01928446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablets will be administered for the duration of follow-up (1 year).
Trial: NCT03449706
Drug: Early combination anti-retroviral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are started on treatment to supress the HIV virus in the phase of acute seroconversion.
Trial: NCT04097145
Drug: Optimal Medical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal Medical Therapy alone in patients with tricuspid regurgitation